Kiadis Pharma NV products

Our IntelliSelect® Transgenic platforms utilize the immune system’s natural mechanisms to create fully-human antibodies that are mature or evolved to be highly specific for their target. We have achieved this by creating several strains of mice in which a complete set of human antibody genes and their landscape of surrounding human genomic DNA was carefully reconstructed in the mouse. The human antibody gene loci in our IntelliSelect® Transgenic platforms mirror those in a human because we utilize the full expanse of the sequence found in humans.

Accessing a new repertoire of targets. Two classes of molecule with therapeutic potential that are not currently addressed by antibody drugs are G-protein-coupled receptors and ion channels, largely because they display small epitopes not accessible to traditional antibodies and their sequence is often conserved and thus less likely to be antigenic.

We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like properties.